Author: Mathilde ROUMIER; Romain PAULE; Matthieu GROH; Alexandre VALLEE; Felix ACKERMANN
Title: Interleukin-6 blockade for severe COVID-19 Document date: 2020_4_22
ID: 0ou5f158_6
Snippet: Between March 21 st 2020 and April 2 nd 2020, 30 patients (80% males; median age: 50 years) were treated with tocilizumab, including 7 (23%) in the setting of Intensive Care Unit (ICU) ( Table 1) . After a median (IQR) follow-up of 8 (6.0-9.75) days, and by comparison with a control group of patients (matched for age, gender and disease severity using the inverse probability of treatment weighted methodology with SAS software) (7) that did not re.....
Document: Between March 21 st 2020 and April 2 nd 2020, 30 patients (80% males; median age: 50 years) were treated with tocilizumab, including 7 (23%) in the setting of Intensive Care Unit (ICU) ( Table 1) . After a median (IQR) follow-up of 8 (6.0-9.75) days, and by comparison with a control group of patients (matched for age, gender and disease severity using the inverse probability of treatment weighted methodology with SAS software) (7) that did not receive tocilizumab, IL-6 blockade significantly reduced the requirement of subsequent mechanical ventilation (weighted OR: 0.42; 95%CI[0,20-0,89]; p=0,025).
Search related documents:
Co phrase search for related documents- control group and disease gender age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- control group and disease gender age severity: 1, 2, 3, 4, 5, 6, 7
- control group and inverse probability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- control group and IQR median: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and mechanical ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and median age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and patient control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- control group and patient control group comparison: 1
- control group and SAS software: 1, 2
- control group and tocilizumab receive: 1, 2, 3, 4
- control group and tocilizumab treat: 1
- control group and treatment inverse probability: 1, 2, 3, 4, 5, 6, 7
- disease gender and IQR median: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- disease gender and mechanical ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease gender and median age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease gender and patient control group: 1, 2
- disease gender and SAS software: 1
- disease gender and tocilizumab receive: 1
- disease gender and treatment inverse probability: 1
Co phrase search for related documents, hyperlinks ordered by date